Conflicting or complementary role of computed tomography (CT) and positron emission tomography (PET)/CT in the assessment of thymic cancer and thymoma: our experience and literature review

Elena Scagliori1, Laura Evangelista2, Annalori Panunzio1, Fiorella Calabrese3, Nazarena Nannini3, Roberta Polverosi4 & Fabio Pomerri1

1 Oncologic Radiology Unit, Veneto Institute of Oncology Iovi – IRCCS, Padua, Italy
2 Radiotherapy and Nuclear Medicine Unit, Veneto Institute of Oncology Iovi – IRCCS, Padua, Italy
3 Department of Cardiac, Thoracic and Vascular Science, University of Padua, Padua, Italy
4 Department of Radiology, Hospital of San Donà di Piave, Venice, Italy

Keywords
Computed tomography; PET/CT; prognosis; thymic cancer; thymoma.

Abstract
Background: To evaluate the role of computed tomography (CT) and positron emission tomography (PET)/CT in patients with thymic cancer and thymoma at initial staging.
Methods: We retrospectively reviewed CT and PET/CT scans of 26 patients with a thymic cancer (n = 9) or thymoma (n = 17). Chest CT findings documented were qualitative and quantitative. Both qualitative and semiquantitative data were recovered by PET/CT. The comparisons among histological entities, outcome, and qualitative data from CT and PET/CT were made by non-parametric analysis.
Results: PET/CT resulted positive in 15/17 patients with thymoma. CT was available in 5/9 (56%) patients with thymic cancer and in 3/17 with thymoma. All quantitative CT parameters were significantly higher in patients with thymic cancer than thymoma (maximum axial diameter: 45 vs. 20 mm, maximum longitudinal diameter: 69 vs. 21 mm and volume: 77.91 vs. 4.52 mL; all \( P < 0.05 \)). Conversely, only metabolic tumor volume (MTV) and total lesion glycolysis were significantly different in patients with thymic cancer than thymoma (126.53 vs. 6.03 cm\(^3\) and 246.05 vs. 20.32, respectively; both \( P < 0.05 \)). After a median follow-up time of 17.45 months, four recurrences of disease occurred: three in patients with thymic cancer and one with a type B2 thymoma. CT volume in patients with recurrent disease was 102.19 mL versus a median value of 62.5 mL in six disease-free patients. MTV was higher in the recurrent than disease-free patient subset (143.3 vs. 81.13 cm\(^3\)), although not statistically significant (\( P = 0.075 \)).
Conclusion: Our preliminary results demonstrated that both morphological and metabolic volume could be useful from a diagnostic and prognostic point of view in thymic cancer and thymoma patients. A large multi-center clinical trial experience for confirming the findings of this study seems mandatory.

Introduction
Thymoma is a rare tumor accounting for <1% of all adult malignancies, although it is the most common primary neoplasm of the anterior mediastinum. Thymoma is the most common thymic epithelial neoplasm; however, thymic carcinoma and thymic carcinoid are also recognized. Because thymoma is a rare disease, an international collaboration and a dedicated work group have been created, the International Thymic Malignancy Interest Group (ITMIG). To facilitate collaborative research efforts and formation of a uniform thymoma database, ITMIG has adopted the Masaoka-Koga staging system as the official staging system for thymoma. This system is based on gross operative findings with microscopic confirmation of invasive tumor properties. Conversely, the World Health Organization (WHO) classification
distinguishes thymic lesions according to their histological pattern. Both the WHO histologic classification of thymic epithelial tumor1,2 and the clinic-pathologic staging system proposed by Masaoka et al.3 have been reported to reflect the oncological behavior of thymoma and, hence, the prognosis.

Imaging plays a role in thymoma identification, extension, global staging, restaging, and evaluation of response to treatment. Initial investigation of thymoma starts with a chest radiograph followed by chest-computed tomography (CT) and is rarely completed by magnetic resonance imaging (MRI) or nuclear medicine studies (such as 111In-octreoscan scintigraphy or positron emission tomography [PET] with 18F-Fluorodeoxyglucose [FDG]).

The purposes of the present study were: (i) to evaluate the role of CT and FDG PET/CT in thymic lesions in initial staging, (ii) to correlate imaging findings with the prognosis of thymic lesions, and (iii) to compare our findings with current literature.

Materials and methods

Patient population

From April 2008 to December 2012, we retrospectively reviewed a total of 90 FDG PET/CT scans that were performed on 56 patients with a known or suspected thymic disease. Moreover, in 32 subjects of the same population, we collected 38 CT scans performed within three months of the PET/CT studies. Thirty-five PET/CT scans were performed at initial staging, 28 for restaging, 17 for evaluation of response to therapy, and 10 for long term follow-up. Out of 38 CT scans, 14 were made at initial staging, eight for restaging, six for response to therapy, and 10 for follow-up. For the end points of the present study, we considered 26 patients at initial staging of thymoma or thymic cancer. There were eight male and 18 female patients (30.8 vs. 68.2%, respectively). The median age was 57.5 years (31–78 years). All patients had a PET/CT scan, while only eight subjects had an available CT in the same setting. The defined diagnosis was obtained by surgical specimens after thymectomy. The surgical specimens were reviewed by two experienced pathologists, and the tumors were divided into six subtypes on the basis of WHO classification: type A, type AB, type B1, type B2, type B3, and thymic carcinoma. All of the tumors were staged on the basis of the presence and extent of transcapsular invasion into adjacent mediastinal tissues as determined by surgical findings and confirmed by microscopic examination:2 stage I, encapsulated tumor without microscopic evidence of capsular invasion; stage II, microscopic or macroscopic invasion of the surrounding fatty tissue or the mediastinal pleura; stage III, macroscopic invasion of neighboring organs, such as the pericardium, lung or the great vessels; and stage IV, pericardial or pleural dissemination (IVA) and lymph node or distant metastases (IVb). This study was approved by the local institutional review board for retrospective analysis, and was conducted according to the Declaration of Helsinki (2000).

Computed tomography (CT) imaging

All chest CT examinations were acquired from the lung apices through the middle portions of both kidneys. Three examinations were made using a 40-row detector CT (Somatom Definition AS; Siemens Medical Systems, Erlangen, Germany) using the following parameters: section thickness 3 mm, reconstruction 2 mm, gantry rotation time 0.5 seconds, pitch 0.8, tube potential 120 kV, and mAs setting adjusted for body weight. All patients received intravenous contrast medium (2 mL/kg; flow rate 3 mL/second; Omnipaque 350; GE Healthcare, Milan, Italy). Imaging data of hard copies in five patients whose CT scans were obtained at other hospitals were scanned and uploaded to a picture archiving and communication system. All monitors showed images obtained using both mediastinal (width, 400 H; level, 20 H) and lung (width 1.500 H, level −700 H) window settings. Multiplanar reconstruction images were assessed for lesion shape and size. CT images were reviewed and interpreted by two radiologists with at least five years experience of chest CT interpretation. Both specialists were presented with the patients’ clinical history, but were unaware of histological findings. Chest CT scans were also retrieved to a commercially available stand-alone workstation loaded with commercial volume CT software (syngo.via, Siemens, Hoffman Estates, IL, USA) which automatically measured the tumor volume by calculating the space that is enclosed within the segmented tumor. Qualitative and quantitative chest CT findings were documented for each patient; in particular, the tumor shape was classified as round if the long-to-short axis ratio was less than or equal to 1.5, oval if the ratio was greater than 1.5 but less than 3.0, and plaque-shaped if the ratio was greater than 3.0. Marginal characteristics were subclassified as smooth, lobulated or irregular. Tumor necrosis and calcifications were considered. The pattern of enhancement was recorded as homogeneous or heterogeneous and the degree of enhancement was classified as low or high compared to that of the chest wall muscle. Fatty mediastinal infiltration, great vessel invasion (such as the degree of abutment), pleural and pericardial effusion, and enlarged lymph nodes were evaluated. Among quantitative variables, tumor size (two maximal axial diameters and maximal longitudinal diameter measured by multplanar reconstruction (MPR) and volume (in mL) were computed.

Positron emission tomography (PET)/CT protocol

Whole body FDG PET/CT was performed using a dedicated PET/CT scanner (Biograph 16 HT, Siemens Medical Solu-
According to the formula: $\text{TLG} = \text{MTV} \times \text{SUVavg}$.

**Follow-up**

Data was collected via scripted telephone interviews by a researcher blinded to the patient’s test result and then confirmed by the revision of medical archives or by contacting the patient’s general practitioner. To determine follow-up time, the date of the last examination or consultation was used. Defined events included local or distant recurrence confirmed by biopsy or conventional imaging modalities.

**Literature research strategy**

A computer literature analysis on studies in human subjects was performed to identify articles that evaluated the role of PET or PET/CT, CT, and MRI in thymic disease. Pubmed and Web of Knowledge were used to compile data from 2004 to January 2014, with the following key words: “THYMOMA or Thymic carcinoma” AND “CT” AND “MRI”, “THYMOMA” AND “CT” NOT “PET” and “THYMOMA AND PET.”

Reviews, clinical reports, and editor comments were excluded. Moreover, articles that did not evaluate the role of CT or MRI or FDG PET or PET/CT in adult thymic lesions were also excluded. We found 91 articles for thymoma and CT and MRI without any filters; when we added HUMANS/JOURNALS ARTICLE/ENGLISH LANGUAGE as filters, a total of 24 articles were obtained. Considering the words thymoma AND CT NOT PET, 419 articles were found, for a total of 91 after filters. Of all of the research compiled, eight articles on thymoma and radiologic examinations for initial assessment were recovered. Similarly, 77 reports evaluated the role of FDG PET or PET/CT in thymic disease, but only 12 met the inclusion criteria.

**Statistical analysis**

A non-parametric statistical analysis was used, such as the chi-square, U-Mann Whitney or Wilcoxon test, as appropriate. A $P$-value $<0.05$ was defined as significant. Survival curves were constructed using the Kaplan-Meier method to account for censored survival times and were compared with the log rank test. Progression-free survival was defined as the length of time from the date of PET/CT to any relapse (local or distance recurrence). Statistical analysis was performed with SPSS software (SPSS Inc. Chicago, IL, USA).

**Results**

**Clinical and histopathological data**

Table 1 reports the clinical and histopathological characteristics of the study population. Seventeen (65.4%) patients had a histologically proven thymoma, while nine (34.6%) had a thymic cancer. WHO classification was type A/B in three (11.5%) patients, type B1 in three (11.5%), type B1/B2 in one (3.8%), type B2 in three (11.5%), and type B3 in seven (26.9%) patients. The Masaoka-Koga system was stage I in three (11.5%) patients, stage IIA in six (23%), stage IIB in one (3.8%), stage III in six (23%), stage IVA in four (15.7%), and stage IVB in six (23%) patients. Among nine patients with thymic cancer, one (11.1%) was stage IIB, two (22.2%) were stage III, two (22.2%) were stage IVA, and four (44.5%) were stage IVB.

---

*Thoracic Cancer* 6 (2015) 433–442 © 2014 The Authors. Thoracic Cancer published by Tianjin Lung Cancer Institute and Wiley Publishing Asia Pty Ltd
Of the 17 patients with thymoma, 15 (88.2%) showed a positive PET/CT scan, whereas two had a false-negative finding. On the other hand, 100% of patients with thymic cancer had a positive scan. CT was available in 5/9 (56%) patients with thymic cancer and in 3/17 (17.6%) with thymoma. In all cases, CT clearly identified the primary tumor.

Tumor necrosis, calcifications, fat infiltration, and pleural effusion were more frequent in thymic cancer compared to thymoma. Conversely, infiltration of vessels was reported both in thymic cancer and in thymoma, as illustrated in Table 2. All quantitative CT parameters were significantly higher in patients with thymic cancer than thymoma (median maximum axial diameter: 45 vs. 20 mm, median maximum longitudinal diameter: 69 vs. 21 mm, and median volume: 77.91 vs. 4.52 mL; all \( P < 0.05 \)). Conversely, among semiquantitative PET/CT features, only MTV and TLG were significantly different in patients with thymic cancer than thymoma (Table 3), while SUV\text{max}, SUV\text{avg}, and T/B ratio was similar, although with a trend to increase in thymic cancer. Figure 1 illustrates two examples of CT and PET/CT images in patients with thymic and thymoma cancer, respectively. According to Masaoka clinical staging, 10 (38.5%) patients were at stage I-II and 16 (61.5%) were at stage III-IV. Table 4 demonstrates that maximum longitudinal diameter,

---

**Table 1** Characteristics of study population

| Characteristics                        | Median age (range), years | Histological subtype, n (%) | Stage, n (%) | Gender, n (%) | Median volume (range) |
|----------------------------------------|---------------------------|-----------------------------|--------------|---------------|-----------------------|
|                                        |                           |                             |              |               | CT (morphological), mL | PET/CT (metabolic), cm³ |
| Median age (range), years              | 57.5 (31–78)              | 3 (11.5%)                   | I            | Male          | 62.5 (3.30–306.9)     | 83.5 (0.06–690)         |
| Histological subtype, n (%)           |                           |                             | II           | Female        |                       |                       |
| Thymoma AB                             |                           | 3 (11.5%)                   | II           |               |                       |                       |
| Thymoma B1                             |                           | 3 (11.5%)                   | III          |               |                       |                       |
| Thymoma B1/B2                          |                           | 1 (3.8%)                    | IVA          |               |                       |                       |
| Thymoma B2                             |                           | 3 (11.5%)                   | IVB          |               |                       |                       |
| Thymoma B3                             |                           | 7 (26.9%)                   |               |               |                       |                       |
| Thymic cancer                          |                           | 9 (34.6%)                   |               |               |                       |                       |
| Stage, n (%)                           |                           |                             |              |               |                       |                       |
| I                                      | 3 (11.5%)                 |                             |              |               |                       |                       |
| II                                     | 7 (26.9%)                 |                             |              |               |                       |                       |
| III                                    | 6 (23.1%)                 |                             |              |               |                       |                       |
| IVA                                    | 14 (15.4%)                |                             |              |               |                       |                       |
| IVB                                    | 6 (23.1%)                 |                             |              |               |                       |                       |
| Gender, n (%)                          |                           |                             |              |               |                       |                       |
| Male                                   | 8 (30.8%)                 |                             |              |               |                       |                       |
| Female                                 | 18 (69.2%)                |                             |              |               |                       |                       |
| Median volume (range)                  |                           |                             |              |               |                       |                       |
| CT (morphological), mL                 |                           |                             |              |               | 62.5 (3.30–306.9)     | 83.5 (0.06–690)         |
| PET/CT (metabolic), cm³                |                           |                             |              |               |                       |                       |

---

**Table 2** Computed tomography characteristics

| Necrosis | Thymic cancer (n = 5) | Thymoma (n = 3) | P-value |
|----------|-----------------------|----------------|---------|
|          | 2 (60%)               | 0              | 0.673*  |
|          | 2 (40%)               | 0              | 0.673*  |
|          | 4 (80%)               | 0              | 0.144*  |
|          | 3 (60%)               | 3 (100%)       | 0.673*  |
|          | 2 (40%)               | 0              | 0.673*  |
|          | 45 (28–80)            | 20 (15–27)     | 0.025** |
| Median maximum longitudinal diameter (in mm) | 69 (24–109) | 21 (3–22) | 0.025** |
| Median volume (in mL)                      | 77.91 (10.5–251) | 4.52 (3.30–7.10) | 0.025** |

---

**Table 3** PET/CT characteristics

| SUVmax | Thymic cancer (n = 9) | Thymoma (n = 17) | P-value |
|--------|-----------------------|-----------------|---------|
|        | 9.34 (3.2–23.5)       | 4.84 (1.5–25.9) | 0.100   |
|        | 4.75 (2.98–8.28)      | 3.39 (0.78–8.85) | 0.247   |
|        | 3.07 (1.67–3.79)      | 2.06 (0.63–5.05) | 0.112   |
| MTV    | 126.53 (0.4–690.02)   | 6.03 (0.06–240.21) | 0.043   |
| TLG    | 642.05 (1.10–3374.20) | 20.32 (0.05–1570.97) | 0.056   |

---

**PET/CT and CT findings**

Of the 17 patients with thymoma, 15 (88.2%) showed a positive PET/CT scan, whereas two had a false-negative finding. On the other hand, 100% of patients with thymic cancer had a positive scan. CT was available in 5/9 (56%) patients with thymic cancer and in 3/17 (17.6%) with thymoma. In all cases, CT clearly identified the primary tumor.

Tumor necrosis, calcifications, fat infiltration, and pleural effusion were more frequent in thymic cancer compared to thymoma. Conversely, infiltration of vessels was reported both in thymic cancer and in thymoma, as illustrated in Table 2. All quantitative CT parameters were significantly higher in patients with thymic cancer than thymoma (median maximum axial diameter: 45 vs. 20 mm, median maximum longitudinal diameter: 69 vs. 21 mm, and median volume: 77.91 vs. 4.52 mL; all \( P < 0.05 \)). Conversely, among semiquantitative PET/CT features, only MTV and TLG were significantly different in patients with thymic cancer than thymoma (Table 3), while SUV\text{max}, SUV\text{avg}, and T/B ratio was similar, although with a trend to increase in thymic cancer. Figure 1 illustrates two examples of CT and PET/CT images in patients with thymic and thymoma cancer, respectively. According to Masaoka clinical staging, 10 (38.5%) patients were at stage I-II and 16 (61.5%) were at stage III-IV. Table 4 demonstrates that maximum longitudinal diameter,
volume at CT, MTV, and TLG at PET were significantly higher in patients at stage III-IV than those at stage I-II.

**Analysis of literature research**

From the collection of published papers on FDG PET/CT, it emerged that four studies have compared mean SUVmax among low and high-risk thymoma, and thymic cancer patients.4–7 The median SUVmax in 175 patients were 4.48, 6.75, and 10.80 for low and high-risk thymoma, and thymic cancer, respectively. As shown in Figure 2a, a slight overlap was found between the three categories. Conversely, the median SUVmax of thymoma and thymic cancer, obtained from 95 patients enrolled in another four studies,8–11 were 3.37 and 8.68, showing a large gap (Fig 2b). Moreover, considering studies that evaluated the relationship between CT measures and thymic disease, we found that in non-invasive thymoma, morphological characteristics were substantially similar to the results of Priola et al.12 and Tomiyama et al.13 In particular, smooth contour, homogeneous enhancement, and partial mediastinal fat infiltration were detected in >50% of patients. Conversely, only the presence of lobulated contours was equally distributed in both patient populations, while the residual CT data (such as necrotic or cystic component and calcifications) were different. Studies by Sadohara et al.,14 Jeong et al.,15 and Liu et al.16 focused on the differentiation among low and high-risk thymoma, and thymic cancer. According to their results, a similar distribution was found for homogeneous contours in low-risk thymoma, for lobulated contours in high-risk thymoma, and for the presence of necrotic or cystic components and heterogeneous enhancement in thymic cancer.

**Table 4** Masaoka clinical staging and semiquantitative imaging findings

| CT | PET/CT |
|----|--------|
| | MLD     | Volume  | MTV      | TLG      |
|---|---------|---------|---------|---------|
| Stage I-II | 21.5 (3–69) | 5.81 (3.30–54.78) | 0.34 (0.06–118.91) | 1.15 (0.05–912.04) |
| Stage III-IV | 73 (24–109) | 77.9 (10.5–306.9) | 95.08 (0.34–690.02) | 466.45 (1.01–3374.20) |
| P-value | 0.026   | 0.013   | 0.003   | 0.003   |

CT, computed tomography; MLD, ***; MTV, metabolic tumor volume; PET, positron emission tomography; TLG, total lesion glycolysis.
Outcome

After a median follow-up of 17.45 months (range: 1–50 months), four patients experienced a recurrence of disease: three in patients with thymic cancer and one with a type B2 thymoma. Follow-up data were lost in three subjects. The median CT volume in two patients with recurrent disease was 102.19 mL versus 62.50 mL in six disease-free patients ($P = 0.865$). MTV and TLG were higher in the recurrent than in the disease-free patient subset (143.3 vs. 81.13 and 756.8 cm$^3$ vs. 322.31, respectively); however, these results were not statistically significant ($P = 0.075$ and 0.118). In Kaplan-Meier analysis, a MTV and a TLG higher than 83.5 cm$^3$ and 371.3, respectively, was associated with a poor prognosis (Fig 3).

Discussion

In the present study, we retrospectively analyzed the morphological and metabolic measurements of a patient series with thymoma and thymic cancer using CT and PET/CT examinations at initial staging of disease. The main purpose of our study was to define the role of CT and PET/CT in patients with thymoma and thymic cancer, in order to help clinicians and surgeons in the management of these diseases, considering the strong support of histological data. Nowadays, both CT and PET/CT are employed in patients with thymic cancer, particularly for defining the extension of disease and for determining the clinical stage. We would like to underline that PET/CT and CT can be interpreted both by visual anal-
sis and by a semiquantitative/quantitative point of view. These latter criteria could be useful in clinical practice to distinguish between low and high disease staging and between poor and good prognoses.

Table 5 reports the list of studies in the literature research.4–23 The majority of reports concerning FDG PET or PET/CT focused on the differences between semiquantitative data and histological patterns.4,6–9,14–17,19,22,23 In particular, Igai et al.,6 Sung et al.,7 Benveniste et al.,4 Fukumoto et al.,8 and Lococo et al.17 concluded that there was a significant difference in SUVmax between the thymoma and thymic carcinoma groups, indicating that this parameter may be useful for discriminating thymoma from thymic carcinoma. In an analysis of 95 patients, SUVmax differentiated patients with thymoma from thymic cancer (see Fig 2b). It is probable that the inclusion of low-risk thymoma patients in the analysis of semiquantitative PET data could lead to lower SUVmax results than if the study only included high-risk thymoma and thymic cancer patients (see Fig 2a). Conversely, in the present study we observed an increasing tendency of SUVmax and tumor/background (T/B) ratio according to thymoma and thymic carcinoma, although this was not statistically significant. On the other hand, MTV shows a significantly different value in thymoma patients (2015) 433–442 © 2014 The Authors. Thoracic Cancer published by Tianjin Lung Cancer Institute and Wiley Publishing Asia Pty Ltd at stage I-II from those at stage III-IV. In accordance with Maroon et al.,20 we considered MPR, whereas the majority of studies based their measurement on axial plane alone.

The advantage of using both anatomical and metabolic volumes would be evident in a more accurate evaluation of disease extension. In fact, stage I is classified as completely encapsulated tumor, stage II as microscopic transcapsular invasion (IIa) or macroscopic invasion into thymic or surrounding fatty tissue (IIb), stage III as macroscopic invasion into neighboring organ (i.e. pericardium, great vessel or lung), and stage IV as pericardial or pleural metastases (IVA) or lymphogeneous or hematogenous metastases (IVB). Therefore, stage I and IIa tumors are confined in the thymic capsule while stage IIb –III and IV are characterized by an infiltrative form that can be associated with a longitudinal extension, rather than posterior-anterior growth. Therefore, CT image measurement based on three perpendiculard diameters should be used for the evaluation of thymic lesions. Similarly, metabolic volume by PET could prompt more clinical data.

None of the studies listed in Table 5 evaluated the prognostic role of CT or PET/CT in thymic neoplasms. As reported by Lococo et al.,17 while there is a body of evidence suggesting that PET SUVmax could reflect the rate of proliferation and degree of invasiveness of thymic neoplasms – thus providing a useful index for diagnosis and treatment – its prognostic role is still debated and remains controversial. Following the lines of extreme simplification we may suppose with a logical assertion that SUVmax and SUVmax/T index may indeed have a prognostic value in thymic neoplasms, directly associated to the different risk classes; however, to date there is no evidence or robust data supporting this assumption. In our study we found that high MTV and TLG (>83.5 cm3 and 371.3, respectively) were associated with a poorer prognosis in this setting of patients. A low rate of recurrence (n = 4/26; 15.4%) was reported in the present study. Although no unique prognostic factor has been identified, several studies have indicated the importance of clinical features (i.e. age and the presence or absence of myasthenia gravis), Masaoka staging, the completeness of surgical resection, WHO histologic type, size of tumor, and great vessel or mediastinal invasion as predictors of recurrence and survival after surgical resection. Patients in stage I and II with a high-risk thymoma have a significantly poorer prognosis (higher recurrence rate and reduced survival) than those with a low-risk thymoma.24 Based on this data, we found that MLD, volume at CT, MTV and TLG at PET were significantly higher in patients at stage III-IV than those at stage I-II and, therefore, directly correlated with prognosis. In addition, we found that after 18 months of follow-up in two patients with disease recurrence, the volume of the tumor in CT images was larger than in patients free of disease.

All selected patients were treated by surgical resection, in some cases associated with chemotherapy (n = 13; as neoadjuvant or adjuvant) and/or adjuvant radiotherapy (n = 5). Although the association between prognosis and therapeutic regimen is beyond the aim of the present study, we indirectly found that combined therapeutic modalities have an important impact on the event-free survival rate. In fact, in our patient population, only four recurrences occurred after 18 months of follow-up.
Table 5: The list of collected studies (in publication date order)

| Authors, ref | Year | N | PTS | Histology (thymoma/thymic cancer) | Imaging | Aim of the study | Conclusions |
|-------------|------|---|-----|----------------------------------|--------|-----------------|-------------|
| Benveniste et al.1 | 2013 | 51 | 3/7/12 (2 thymic carcinoid) | FDG PET | To assess whether the amount of FDG uptake can predict advanced thymoma and if it can separate thymoma from thymic cancer. | Focal FDG uptake cannot predict advanced thymoma but is helpful in distinguishing thymoma from thymic carcinoma or more aggressive forms, such as thymic B3. |
| Toda et al.2 | 2013 | 33 | 25/8 | FDG PET/CT | To evaluate the usefulness of FDG PET/CT and the relationship among the expression of HIF-1, Glut-1, and VEGF. | The expression of HIF-1, Glut-1, and VEGF might be associated with malignancy of thymic epithelial tumors. |
| Lucoce et al.7 | 2013 | 47 | 4/07 | PET/CT FDG | To determine the performance of combined FDG PET/CT as a predictor of the WHO classification based malignancy grade in thymic epithelial tumors. | A significant correlation between FDG PET/CT and WHO classification was found. |
| Qu et al.8 | 2013 | 129 | 129/0 | CT PET/CT | To investigate the relationships between preoperative CT staging and postoperative surgical staging and postoperative Masaoka clinical staging. | This study documented a dose relationship between preoperative CT thymoma staging and postoperative Masaoka clinical staging. Thus, preoperative CT findings can be beneficial for determining the proper management and prognosis of thymoma patients. |
| Liu et al.9 | 2012 | 105 | 105/1 | CT | To explore the relationship between CT manifestations of thymoma and its WHO pathological classification. | Distinctive CT features of thymomas may reflect their pathological types. |
| Fukuimoto et al.10 | 2012 | 58 | 24/4 | PET/CT FDG | To assess the utility of FDG PET/CT for predicting the histologic type and stage of thymic epithelial tumors. | PET/CT could be used to identify patients with high-risk thymomas and modify clinical management following histological confirmation or modify surgical approach (open vs. thoracoscopic surgery). |
| Tezzi et al.11 | 2011 | 26 | 1/88 | FDG PET | To assess the usefulness of PET in thymic epithelial tumors for determining the grade of malignancy of thymic epithelial neoplasms, and to modify treatment strategy. | The expression of HIF-1, Glut-1 and VEGF might be associated with malignancy of thymic epithelial tumors. |
| Igai et al.12 | 2011 | 13 | 8/5 | PET/CT FDG | To investigate whether SUVmax can predict the grade of malignancy of thymic epithelial tumors based on the WHO classification. | SUVmax is a useful parameter for differentiating between thymic epithelial tumor subgroups and for evaluating the extent of disease. |
| Marom et al.13 | 2011 | 99 | 9/90 | CT PET | To identify preoperative CT findings associated with thymoma invasiveness before surgical resection. | PET/CT can characterize the CT features of common anterior mediastinal tumors and evaluate CT findings that may help in suggesting specific diagnosis among these tumors. |
| Piola et al.14 | 2010 | 50 | 5/80 | CT PET/CT FDG | To assess the CT imaging findings of thymoma and to correlate these features with Masaoka staging system and prognosis. | The expression of HIF-1, Glut-1 and VEGF might be associated with malignancy of thymic epithelial tumors. |
| Tatananurongse et al.15 | 2010 | 28 | 2/71 | CT PET/CT FDG | To characterize the CT features of common anterior mediastinal tumors and evaluate CT findings that may help in suggesting specific diagnosis among these tumors. | PET/CT can characterize the CT features of common anterior mediastinal tumors and evaluate CT findings that may help in suggesting specific diagnosis among these tumors. |
| Kumar et al.16 | 2009 | 23 | 1/94 | FDG PET/CT PET/CT FDG | To evaluate if FDG PET/CT can help differentiate various thymic lesions noted on preoperative imaging studies. | The expression of HIF-1, Glut-1 and VEGF might be associated with malignancy of thymic epithelial tumors. |
| Luzi et al.17 | 2009 | 19 | 1/36 | PET FDG PET/CT PET/CT FDG | To explore the usefulness of FDG PET/CT in the preoperative assessment of isolated anterior mediastinal lesions. | PET/CT can characterize the CT features of common anterior mediastinal tumors and evaluate CT findings that may help in suggesting specific diagnosis among these tumors. |
| Shibata et al.18 | 2009 | 40 | 3/73 | FDG PET/CT FDG PET/CT FDG | To clarify the usefulness of PET using FDG and 11C-acetate for predicting the histologic types and tumor invasiveness of thymoma. | PET/CT can characterize the CT features of common anterior mediastinal tumors and evaluate CT findings that may help in suggesting specific diagnosis among these tumors. |
| Tomyama et al.19 | 2009 | 60 | 4/812 | FDG PET/CT PET/CT PET/CT FDG | To compare the diagnostic accuracy for anterior mediastinal tumors among CT, MRI, and both CT and MRI, and to determine the optimal CT and MRI procedures for the diagnosis of anterior mediastinal tumors. | PET/CT can characterize the CT features of common anterior mediastinal tumors and evaluate CT findings that may help in suggesting specific diagnosis among these tumors. |
| Endo et al.20 | 2008 | 36 | 3/60 | FDG PET/CT FDG PET/CT PET/CT FDG | To assess the value of FDG PET in thymic epithelial tumors according to the WHO histological classification. | PET/CT can characterize the CT features of common anterior mediastinal tumors and evaluate CT findings that may help in suggesting specific diagnosis among these tumors. |
| El-Bawab et al.21 | 2007 | 37 | 3/70 | PET/CT FDG PET/CT PET/CT FDG | To evaluate the value of PET scan with FDG in thymic pathology. | PET/CT can characterize the CT features of common anterior mediastinal tumors and evaluate CT findings that may help in suggesting specific diagnosis among these tumors. |
| Saddhara et al.22 | 2006 | 60 | 4/812 | PET/CT FDG PET/CT PET/CT PET/CT | To assess the CT and MRI findings of thymic epithelial tumors classified according to the current WHO histological classification and to determine useful findings in differentiating the main subtypes. | PET/CT can characterize the CT features of common anterior mediastinal tumors and evaluate CT findings that may help in suggesting specific diagnosis among these tumors. |
| Sung et al.23 | 2006 | 33 | 1/716 | FDG PET/CT PET/CT PET/CT PET/CT PET/CT PET/CT | To assess the usefulness of integrated PET/CT using FDG for distinguishing thymic epithelial tumors according to the WHO classification. | PET/CT can characterize the CT features of common anterior mediastinal tumors and evaluate CT findings that may help in suggesting specific diagnosis among these tumors. |
| Jeong et al.24 | 2004 | 91 | 7/615 | PET/CT PET/CT PET/CT PET/CT PET/CT PET/CT | To describe the CT findings of thymic epithelial tumors and to correlate these findings with histopathological subtypes and prognosis. | PET/CT can characterize the CT features of common anterior mediastinal tumors and evaluate CT findings that may help in suggesting specific diagnosis among these tumors. |

CT, computed tomography; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography; SUVmax, standardized uptake value maximum; VEGF, vascular endothelial growth factor; WHO, World Health Organization.
The present study has some limitations: (i) different types of CT scanner were used, including hard copies of scans in five patients; (ii) a small number of patients were included and a retrospective design was used; and (iii) a short period of follow-up could be correlated with a lower number of events. Particularly, the fact of the small sample size cannot, therefore, determine a solid conclusion, and should be considered a major limitation. The low incidence of the disease also represents a limit to clinical trials.

Conclusions

Both morphological and metabolic volume can be useful from a diagnostic and prognostic point of view in thymic cancer and thymoma patients. The association of CT and PET/CT images in a single step examination employing a dedicated protocol, such as respiratory gating, could be useful for providing complete tumor information. A large multicenter clinical trial for confirming the findings of this study is mandatory.

Disclosure

No authors report any conflict of interest.

References

1. Rosai J, Sobin LH. Histological typing of tumours of the thymus. 2nd edn. Springer, New York 1999.
2. Sonobe S, Myamoto H, Izumi H et al. Clinical usefulness of the WHO histological classification of thymoma. Ann Thorac Cardiovasc Surg 2005; 11: 367–73.
3. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981; 48: 2485–92.
4. Benveniste MF, Moran CA, Mawlawi O et al. FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies. J Thorac Oncol 2013; 8: 502–10.
5. Toba H, Kondo K, Sadohara Y et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1α, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours. Eur J Cardiothorac Surg 2013; 44: e105–12.
6. Fukumoto K, Taniguchi T, Ishikawa Y et al. The utility of [18F]-fluorodeoxyglucose positron emission tomography-computed tomography in thymic epithelial tumours. Eur J Cardiothorac Surg 2012; 42: e152–6.
7. Sung YM, Lee KS, Kim BT, Choi JY, Shim YM, Yi CA. 18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups. J Nucl Med 2006; 47: 1628–34.
8. Igai H, Matsuura N, Tarumi S et al. Usefulness of [18F]fluoro-2-deoxy-D-glucose positron emission tomography for predicting the World Health Organization malignancy grade of thymic epithelial tumors. Eur J Cardiothorac Surg 2011; 40: 143–5.
9. Kumar A, Regmi SK, Dutta R et al. Characterization of thymic masses using (18)F-FDG PET-CT. Ann Nucl Med 2009; 23: 569–77.
10. Luzzi L, Campione A, Gorla A et al. Role of fluorine-fluorodeoxyglucose positron emission tomography/computed tomography in preoperative assessment of anterior mediastinal masses. Eur J Cardiothorac Surg 2009; 36: 475–9.
11. Shibata H, Nomori H, Uno K et al. 18F-fluorodeoxyglucose and 11C-acetate positron emission tomography are useful modalities for diagnosing the histologic type of thymoma. Cancer 2009; 115: 2531–8.
12. Priola AM, Priola SM, Di Franco M, Cataldi A, Durando S, Fava C. Computed tomography and thymoma: distinctive findings in invasive and noninvasive thymoma and predictive features of recurrence. Radiol Med 2010; 115: 1–21.
13. Tomiyama N, Honda O, Tsukamoto M et al. Anterior mediastinal tumors: diagnostic accuracy of CT and MRI. Eur J Radiol 2009; 69: 280–8.
14. Sadohara J, Fujimoto K, Müller NL et al. Thymic epithelial tumors: comparison of CT and MR imaging findings of low-risk thymomas, high-risk thymomas, and thymic carcinomas. Eur J Radiol 2006; 60: 70–9.
15. Jeong YJ, Lee KS, Kim J, Shim YM, Han J, Kwon OJ. Does CT of thymic epithelial tumors enable us to differentiate histologic subtypes and predict prognosis? AJR Am J Roentgenol 2004; 183: 283–9.
16. Liu GB, Qu YJ, Liao MY, Hu HJ, Yang GF, Zhou SJ. Relationship between computed tomography manifestations of thymic epithelial tumors and the WHO pathological classification. Asian Pac J Cancer Prev 2012; 13: 5581–5.
17. Lococo F, Cesario A, Okami J et al. Role of combined 18F-FDG-PET/CT for predicting the WHO malignancy grade of thymic epithelial tumors: a multicenter analysis. Lung Cancer 2013; 82: 245–51.
18. Qu YJ, Liu GB, Shi HS, Liao MY, Yang GF, Tian ZX. Preoperative CT findings of thymoma are correlated with postoperative Masaoka clinical stage. Acad Radiol 2013; 20: 66–72.
19. Terzi A, Bertolaccini L, Rizzardi G et al. Usefulness of 18-F FDG PET/CT in the pre-treatment evaluation of thymic epithelial neoplasms. Lung Cancer 2011; 74: 239–43.
20. Marom EM, Miltio MA, Moran CA et al. Computed tomography findings predicting invasiveness of thymoma. J Thorac Oncol 2011; 6: 1274–81.
21. Totanarungroj K, Watcharaporn C, Muangman N. Helpful CT findings for giving specific diagnosis of anterior mediastinal tumors. J Med Assoc Thai 2010; 93: 489–96.
22 Endo M, Nakagawa K, Ohde Y et al. Utility of 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors. Lung Cancer 2008; 61: 350–5.
23 El-Bawab H, Al-Sugair AA, Rafay M, Hajjar W, Mahdy M, Al-Kattan K. Role of fluorine-18 fluorodeoxyglucose positron emission tomography in thymic pathology. Eur J Cardiothorac Surg 2007; 31: 731–6.
24 Okumura M, Ohta M, Tateyama H et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002; 94: 624–32.